IRCT20201028049175N3 IRCT 2021-01-15 Arak University of Medical Sciences Effect of Atorvastatin to decrease intensity of clinical manifestations in patient with COVID19 Effect of Atorvastatin to decrease intensity of clinical manifestations in patient with COVID19 2021-02-19 anticipated 100 Complete https://irct.ir/trial/53410 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: Patients will be allocated into two groups using a permuted balanced block randomization method with the size of blocks 4 and 6. Random sequence will be generated by an epidemiologist by running an online program in sealed envelope website (https://www.sealedenvelope.com/). Concealment is also guaranteed due to the use of permuted balanced block randomization method, Blinding description: Patients blindness: Both kinds of tablets(Atorvastatin and flour tablet) are similar in shape and time of use. Nurses blindness: Preparation and appropriation of drugs will be accomplished by the physician. 3 Coronavirus Disease 2019 (COVID19). Intervention 1: Intervention group: Atorvastatin 40 mg tablet orally (or with gavage in intubated patients) will be added to routine treatment protocol for 10 days from first day of hospitalization. Intervention 2: Control group:Placebo drug (flour tablet) which is similar to Atorvastatin in its shape and size will be given to the patients for 10 days from first day of hospitalization (in addition to routine treatment). Undecided - It is not yet known if there will be a plan to make this available Justification or reason for indecision in sharing IPD is There are no more data.